Scilex Holding (SCLX) Cash from Investing Activities (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Cash from Investing Activities of -$9.2 million for Q1 2026, down 2218.99% year-over-year from $432282.0 in Q1 2025, and down 291.47% on a QoQ basis from $4.8 million in Q4 2025.
Scilex Holding (SCLX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Cash from Investing Activities for 6 consecutive years, with -$9.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 2218.99% year-over-year to -$9.2 million; the TTM figure through Mar 2026 stood at -$4.7 million (down 60.31% YoY), while the FY2025 annual figure was $4.1 million, up 252.67% from the prior year.
- Cash from Investing Activities came in at -$9.2 million for Q1 2026 at Scilex Holding, down from $4.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $4.8 million in Q4 2025, with the low at -$9.2 million in Q1 2026.
- Average Cash from Investing Activities over 5 years is -$676533.3, with a median of -$155000.0 recorded in 2023.
- Across the five-year window, Cash from Investing Activities soared 2553.33% in 2025 and sank 2218.99% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at -$7000.0 in 2022, then plunged by 2285.71% to -$167000.0 in 2023, then slipped by 16.77% to -$195000.0 in 2024, then jumped by 2553.33% to $4.8 million in 2025, then sank by 291.47% to -$9.2 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$9.2 million, $4.8 million, and -$152000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -3.92 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -1.04 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -574.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -1.79 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -10.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -716.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.77 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 785.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -9.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.16 Mn |
| Mar 31, 2026 | -9.16 Mn |
| Dec 31, 2025 | 4.78 Mn |
| Dec 31, 2025 | 4.78 Mn |
| Sep 30, 2025 | -152,000.00 |
| Sep 30, 2025 | -152,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Dec 31, 2024 | -195,000.00 |
| Dec 31, 2024 | -195,000.00 |
| Sep 30, 2024 | -2.18 Mn |
| Sep 30, 2024 | -2.18 Mn |
| Jun 30, 2024 | -150,000.00 |
| Jun 30, 2024 | -150,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Dec 31, 2023 | -167,000.00 |
| Dec 31, 2023 | -167,000.00 |